SOUTH SAN FRANCISCO, Calif. & HUNTSVILLE, Ala.--(BUSINESS WIRE)--Sequenta and iRepertoire announced today that Sequenta has gained exclusive rights to the iRepertoire intellectual property on novel methods of immune cell sequencing for minimal residual disease (MRD) testing. This intellectual property complements Sequenta’s existing patents on MRD, including its proprietary LymphoSIGHT™ technology. The agreement reinforces Sequenta’s patent portfolio, which strengthens Sequenta’s ability to provide future products and new features and solidifies the company’s position as the MRD market leader.
“This agreement demonstrates our continued commitment to providing the most sensitive and best validated platform for measuring residual disease in lymphoid cancer,” said Tom Willis, chief executive officer of Sequenta. “The complementary technology, intellectual property estate and alignment with Dr. Jian Han, one of the pioneers in immune profiling, will strengthen our position in the MRD testing field and further differentiate our product offerings.”
iRepertoire markets tools for immune profiling, including kits and software. It is also engaged in discovering and developing immune repertoire signatures through its R10k program.
“iRepertoire is excited to be joining forces with the market leader in MRD testing in this important application of immune cell profiling,” said Jian Han, M.D., Ph.D., chief executive officer of iRepertoire. “This deal underscores the value of immune cell profiling and of our platform and will enable us to move our business forward in other areas.”
Earlier this year, Sequenta launched the ClonoSIGHT™ test, a clinical test based on the LymphoSIGHT platform, which works by sequencing unique DNA signatures that are present in immune cells to allow tracking of malignant sub-populations even when they are present at levels as low as one cell per million white blood cells. The technology has been validated in four peer-reviewed publications and presented in over 15 studies at major oncology conferences, including American Society of Hematology (ASH) and American Society for Clinical Oncology (ASCO).
About Sequenta, Inc.
Sequenta is a venture-backed startup dedicated to improving patient care in diseases mediated by immune cells through measurements of lymphocyte diversity. It is commercializing its LymphoSIGHT™ platform for clinical use in minimal residual disease while continuing to validate the use of its technology in a diverse set of diseases. For more information, go to www.sequenta.com.